Loading
Treated the first child with CAR-T cells and led ELIANA, the trial behind the first CAR-T approval.
Stephan Grupp treated Emily Whitehead, the first child to receive CD19 CAR-T cells, in 2012 and led the CHOP trials and the global ELIANA study that won tisagenlecleucel the first-ever CAR-T approval in 2017 for relapsed paediatric ALL. He identified tocilizumab as the treatment for cytokine release syndrome, which made CAR-T deliverable, and directs cellular therapy at CHOP.
| Title | Journal | Year |
|---|---|---|
| Chimeric antigen receptor-modified T cells for acute lymphoid leukemia | NEJM | 2013 |
| Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia (ELIANA) | NEJM | 2018 |
| Maude 2014: CD19 CAR-T cells produce complete remission in 27 of 30 children and adults with relapsed ALL | New England Journal of Medicine | 2014 |
ELIANA turned CAR-T from a single-centre experiment into a licensed product and created the regulatory and logistical template every later cell therapy has followed. For children with refractory leukaemia it offers a chance of durable remission without transplant. The trial also exposed the gaps: manufacturing failures, patients dying while waiting, and roughly half relapsing within a few years.
This paper is the proof-of-concept for a living drug: a single infusion of a patient's own engineered T cells could eradicate leukaemia that had survived chemotherapy, transplant and antibody therapy. It defined cytokine release syndrome and its antidote, tocilizumab, and revealed antigen-loss relapse. It led directly to the first approved gene-modified cell therapy three years later.
Shares CAR-T cell therapy and the tags cell-therapy, car-t, paediatric.
Shares Abramson Cancer Center, University of Pennsylvania, CD19, CAR-T cell therapy and the tags cell-therapy, car-t.
Shares Maude 2014: CD19 CAR-T cells produce complete remission in 27 of 30 children and adults with relapsed ALL, ELIANA: the global trial that made tisagenlecleucel the first approved CAR-T therapy for children and young adults with relapsed ALL, Children's Hospital of Philadelphia, Abramson Cancer Center, University of Pennsylvania.
Shares CD19, CAR-T cell therapy, Acute lymphoblastic leukaemia and the tags cell-therapy, paediatric.
Shares CD19, CAR-T cell therapy, Acute lymphoblastic leukaemia and the tags cell-therapy, car-t.
Shares Maude 2014: CD19 CAR-T cells produce complete remission in 27 of 30 children and adults with relapsed ALL, ELIANA: the global trial that made tisagenlecleucel the first approved CAR-T therapy for children and young adults with relapsed ALL, Abramson Cancer Center, University of Pennsylvania, CAR-T cell therapy.
Shares Maude 2014: CD19 CAR-T cells produce complete remission in 27 of 30 children and adults with relapsed ALL, Abramson Cancer Center, University of Pennsylvania, CD19, CAR-T cell therapy.
Shares CD19, CAR-T cell therapy and the tags cell-therapy, car-t.